We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay Identifies Subtypes of Cancer

By LabMedica International staff writers
Posted on 12 Jun 2012
Print article
A monoclonal antibody has been developed for the measurement of met protooncogene, (MET) expression in formalin fixed paraffin embedded (FFPE) tissues.

The MET4 antibody works exceptionally well with tumors expressing the human hepatocyte growth factor receptor MET oncogene and biopsies using routine immunohistochemical procedures.

The Van Andel Research Institute (VARI; Grand Rapids, MI, USA) and Dako (Glostrup, Denmark), a worldwide supplier of cancer diagnostic tools, have announced an agreement to license, manufacture and distribute cancer diagnostics utilizing the MET4 antibody. The antibody shows accurate detection and quantification, high specificity and consistency, gives robust staining with reduced background. It can detect MET in a wide variety of solid tumors and can detect and facilitate prognosis of the malignancy.

Inappropriate MET activity and signaling occur in human tumors, which can affect the growth of cancer cells. In the past several years, many drugs targeting the hepatocyte growth factor/scatter factor (HGF/SF)-MET pathway have been developed. These include antibodies against HGF/SF, and MET and small-molecule inhibitors of MET activity. Studies currently underway link MET to more than 30 different types of cancer.

Diagnostic tools with the MET4 Antibody will be developed and manufactured by Dako for clinically relevant diagnostic indications and commercialized worldwide. Dako also holds the right to develop MET4 companion diagnostic assays for the pharmDxTM assays in collaboration with pharmaceutical companies to identify cancer patients who may benefit from MET-targeted therapies.

George F. Vande Woude, PhD, a Distinguished Scientific Fellow at VARI, said, "In normal tissue, the MET gene is involved in wound healing and liver repair, but when it is “inappropriately expressed,” it can contribute to the growth of cancer. Studies have shown that targeting MET signaling can have potent antitumor effects, and it is therefore important to identify patient subgroups most likely to benefit from MET-targeted therapies.”

Related Links:

Van Andel Research Institute
Dako

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more